https://www.biopharmawatch.com/news/BMY/bmy-camzyos-long-term-efficacy-esc-congress-2026 BiopharmaWatch en 2026-08-29T15:00:00.000Z Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026 https://www.biopharmawatch.com/news/CYTK/cytokinetics-acacia-hcm-maple-hcm-results-esc-2026 BiopharmaWatch en 2026-08-29T14:30:00.000Z Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026 https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-phase-3-level-results-esc-congress-2026 BiopharmaWatch en 2026-08-29T12:21:00.000Z Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 https://www.biopharmawatch.com/news/TAK/takeda-fda-approval-mimrylo-polycythemia-vera BiopharmaWatch en 2026-08-28T22:40:00.000Z Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera https://www.biopharmawatch.com/news/AIDX/2020-biolabs-investor-webinar-september-2026 BiopharmaWatch en 2026-08-28T22:26:00.000Z 20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity https://www.biopharmawatch.com/news/TRIB/trinity-biotech-diagnostics-update-august-2026 BiopharmaWatch en 2026-08-28T21:15:00.000Z Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update https://www.biopharmawatch.com/news/OGEN/oragenics-clinical-progress-regulatory-update BiopharmaWatch en 2026-08-28T20:25:00.000Z Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update https://www.biopharmawatch.com/news/ZBH/zimmer-biomet-quarterly-dividend-q3-2026 BiopharmaWatch en 2026-08-28T20:15:00.000Z Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2026 https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-nasdaq-noncompliance-letter BiopharmaWatch en 2026-08-28T20:06:17.000Z Shuttle Pharmaceuticals Holdings, Inc. Announces Receipt of NASDAQ Noncompliance Letter https://www.biopharmawatch.com/news/TXG/10x-genomics-patent-infringement-verdict-parse-biosciences BiopharmaWatch en 2026-08-28T18:38:00.000Z 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences https://www.biopharmawatch.com/news/UNH/am-best-affirms-unitedhealth-group-credit-ratings BiopharmaWatch en 2026-08-28T18:27:00.000Z AM Best Affirms Credit Ratings of UnitedHealth Group Incorporated and Its Subsidiaries https://www.biopharmawatch.com/news/NTRA/natera-susan-g-komen-partnership-breast-cancer BiopharmaWatch en 2026-08-28T15:03:00.000Z Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-phase-1a-data-ctx310-esc-2026 BiopharmaWatch en 2026-08-28T14:31:00.000Z CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026 https://www.biopharmawatch.com/news/AGEN/agenus-bot-bal-survival-mss-colorectal-cancer BiopharmaWatch en 2026-08-28T14:07:00.000Z Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism https://www.biopharmawatch.com/news/NTHI/neonc-phase-2a-success-registration-pathway BiopharmaWatch en 2026-08-28T14:07:00.000Z NeOnc’s Phase 2A Success Could Set the Stage for Something Much Bigger https://www.biopharmawatch.com/news/IGC/ascendiant-capital-markets-raises-igc-pharma-price-target BiopharmaWatch en 2026-08-28T13:40:00.000Z Ascendiant Capital Markets Raises IGC Pharma Price Target to $6.00, Citing CALMA Progress and Q4 2026 Topline Catalyst https://www.biopharmawatch.com/news/COSM/cosmos-health-strengthens-balance-sheet-capital-structure BiopharmaWatch en 2026-08-28T13:30:00.000Z Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions https://www.biopharmawatch.com/news/TNON/tenon-medical-3m-private-placement-offering BiopharmaWatch en 2026-08-28T13:00:00.000Z WallachBeth Capital Announces Tenon Medical Pricing of $3M Private Placement Offering https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-south-palm-cardiovascular-agreements BiopharmaWatch en 2026-08-28T12:45:00.000Z Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center https://www.biopharmawatch.com/news/NVAX/novavax-nuvaxovid-approvals-2026-2027 BiopharmaWatch en 2026-08-28T12:30:00.000Z Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season https://www.biopharmawatch.com/news/LH/labcorp-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-08-28T12:30:00.000Z Labcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/IVF/invo-fertility-hc-wainwright-conference-2026 BiopharmaWatch en 2026-08-28T12:30:00.000Z INVO Fertility to Participate in H.C. Wainwright's 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/AMRN/reduce-it-legacy-analysis-esc-congress-2026 BiopharmaWatch en 2026-08-28T12:15:29.000Z New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-expands-intellectual-property-portfolio BiopharmaWatch en 2026-08-28T12:15:00.000Z Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-investor-conferences-2026 BiopharmaWatch en 2026-08-28T12:00:00.000Z Minerva Neurosciences to Participate in Two Upcoming Investor Conferences https://www.biopharmawatch.com/news/FEED/envue-medical-reverse-stock-split BiopharmaWatch en 2026-08-28T12:00:00.000Z ENvue Medical, Inc. Announces 1-for-12 Reverse Stock Split https://www.biopharmawatch.com/news/BLRX/biolinerx-announces-375-million-offering BiopharmaWatch en 2026-08-28T12:00:00.000Z BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-public-offering-120-million BiopharmaWatch en 2026-08-28T11:30:00.000Z Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering https://www.biopharmawatch.com/news/IBIO/ibio-fiscal-year-2026-results-corporate-update BiopharmaWatch en 2026-08-28T11:00:00.000Z iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/UTHR/united-therapeutics-data-esc-ers-congress-2026 BiopharmaWatch en 2026-08-28T11:00:00.000Z United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026 https://www.biopharmawatch.com/news/XRTX/xortx-terminates-investor-relations-program BiopharmaWatch en 2026-08-28T11:00:00.000Z XORTX Announces Termination and Postponement of Investor Relations Program https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-private-placement-financing BiopharmaWatch en 2026-08-28T10:00:00.000Z Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million https://www.biopharmawatch.com/news/IMRN/immuron-fy26-preliminary-results BiopharmaWatch en 2026-08-28T10:00:00.000Z Immuron Reports FY26 Preliminary Results https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-asset-sale-teva-pharmaceuticals BiopharmaWatch en 2026-08-28T10:00:00.000Z BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-positive-interim-data-netherton-syndrome BiopharmaWatch en 2026-08-28T10:00:00.000Z Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome https://www.biopharmawatch.com/news/CYTK/cytokinetics-positive-results-acacia-hcm-esc-2026 BiopharmaWatch en 2026-08-28T09:45:00.000Z Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine https://www.biopharmawatch.com/news/SLBT/sl-science-fda-drug-master-file-gdt-exosomes BiopharmaWatch en 2026-08-28T07:53:03.000Z SL Science 宣布新進展：GDT細胞衍生外泌體，取得 FDA 藥物主檔案登記 https://www.biopharmawatch.com/news/HTFL/heartflow-ffrct-analysis-reduces-invasive-procedures BiopharmaWatch en 2026-08-28T06:48:00.000Z Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half https://www.biopharmawatch.com/news/PHG/philips-imricor-mri-interventional-lab-solution BiopharmaWatch en 2026-08-28T06:46:00.000Z Riassunto: Philips e Imricor lanciano una soluzione per laboratorio di risonanza magnetica interventistica cardiaca, ampliando la loro collaborazione di lunga data https://www.biopharmawatch.com/news/PHG/philips-imricor-interventional-mri-lab-solution BiopharmaWatch en 2026-08-28T06:44:00.000Z Philips et Imricor lancent une solution de laboratoire d'IRM interventionnelle cardiaque, renforçant ainsi leur collaboration de longue date https://www.biopharmawatch.com/news/PHG/philips-imricor-mr-laboratory-solution-launch BiopharmaWatch en 2026-08-28T02:07:00.000Z Samenvatting: Philips en Imricor lanceren een MR-laboratoriumoplossing voor hartingrepen en breiden daarmee hun langdurige samenwerking uit https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-public-offering-120-million BiopharmaWatch en 2026-08-28T00:00:00.000Z Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively ... https://www.biopharmawatch.com/news/LLY/fda-approves-lilly-mounjaro-cardiovascular-risk BiopharmaWatch en 2026-08-28T00:00:00.000Z FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved Mounjaro (tirzepatide), a dual GIP and... https://www.biopharmawatch.com/news/LLY/fda-approves-mounjaro-tirzepatida-reduce-cardiovascular-risk BiopharmaWatch en 2026-08-28T00:00:00.000Z La FDA aprueba Mounjaro (tirzepatida) de Lilly para reducir el riesgo cardiovascular en adultos con diabetes tipo 2 Eli Lilly and Company (NYSE: LLY) anunció hoy que la Administración de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en inglés)... https://www.biopharmawatch.com/news/GILD/fda-approves-gileads-bixlenvo-hiv-treatment BiopharmaWatch en 2026-08-27T21:47:00.000Z U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens https://www.biopharmawatch.com/news/SGP/spyglass-pharma-irvine-headquarters-opening BiopharmaWatch en 2026-08-27T20:40:00.000Z SpyGlass Pharma Celebrates Grand Opening of New Irvine Headquarters, Positioning Itself for First Product Launch and Custom R&D Space https://www.biopharmawatch.com/news/BNTX/pfizer-biontech-fda-approval-xfg-covid-vaccine BiopharmaWatch en 2026-08-27T20:30:29.000Z Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine https://www.biopharmawatch.com/news/PFE/pfizer-biontech-fda-approval-xfg-covid-vaccine BiopharmaWatch en 2026-08-27T20:30:00.000Z Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine https://www.biopharmawatch.com/news/IQV/iqvia-awards-ai-technology-innovation BiopharmaWatch en 2026-08-27T20:15:00.000Z IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare https://www.biopharmawatch.com/news/IMCC/im-cannabis-shares-trading-consolidated-basis BiopharmaWatch en 2026-08-27T20:10:00.000Z IM Cannabis Shares Commence Trading on 30:1 Consolidated Basis https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-public-offering BiopharmaWatch en 2026-08-27T20:09:00.000Z Kazia Therapeutics Limited Announces Proposed Public Offering https://www.biopharmawatch.com/news/BIIB/biogen-participate-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-08-27T20:06:00.000Z Biogen to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/BIIB/biogen-participate-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-08-27T20:06:00.000Z Biogen to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-promotes-nick-smith-president-cfo BiopharmaWatch en 2026-08-27T20:05:00.000Z Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer https://www.biopharmawatch.com/news/QGEN/qiagen-launches-qiaysymphony-connect-nucleic-acid-extraction BiopharmaWatch en 2026-08-27T20:05:00.000Z QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction https://www.biopharmawatch.com/news/AGL/agilon-health-revised-presentation-time-jefferies-conference BiopharmaWatch en 2026-08-27T20:05:00.000Z agilon health Announces Revised Presentation Time at the 2026 Jefferies Healthcare Services and Technology Conference https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-appoints-kevin-lundquist-cfo BiopharmaWatch en 2026-08-27T20:05:00.000Z Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™ https://www.biopharmawatch.com/news/RMD/resmed-participation-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-08-27T20:05:00.000Z Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-paxalisib-triple-negative-breast-cancer BiopharmaWatch en 2026-08-27T20:01:00.000Z Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer https://www.biopharmawatch.com/news/HTFL/heartflow-wells-fargo-healthcare-conference-2026 BiopharmaWatch en 2026-08-27T20:01:00.000Z Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/ACET/adicet-bio-fda-clearance-adi-212 BiopharmaWatch en 2026-08-27T20:00:00.000Z Adicet Bio Announces FDA Clearance of IND Application for ADI-212 https://www.biopharmawatch.com/news/ROIV/roivant-fda-approval-lisraya-dermatomyositis BiopharmaWatch en 2026-08-27T19:29:00.000Z Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. https://www.biopharmawatch.com/news/PHG/philips-imricor-interventional-mr-lab-solution BiopharmaWatch en 2026-08-27T19:27:00.000Z Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration https://www.biopharmawatch.com/news/SYK/stryker-participate-2026-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-27T19:00:00.000Z Stryker to participate in the 2026 Wells Fargo Healthcare Conference